OCA
XENE icon

Octagon Capital Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Octagon Capital Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.6M Hold
490,000
– – 2.66% 12
2026
Q1 		$28.5M Buy
+490,000
New +$22.6M 3.15% 13

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Octagon Capital Advisors's XENE Position: Q2 2026 in Review

Octagon Capital Advisors held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 490,000 shares worth $29.6M. The position accounts for 2.66% of the portfolio, ranked #12.

Octagon Capital Advisors first reported a position in XENE in Q1 2026 and has held it in 2 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Octagon Capital Advisors held 490,000 shares of Xenon Pharmaceuticals worth $29.6M as of Q2 2026.
  • Octagon Capital Advisors left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
  • Xenon Pharmaceuticals made up 2.66% of Octagon Capital Advisors's portfolio in Q2 2026, its #12 holding.
  • Octagon Capital Advisors first reported a position in Xenon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.